Interferon Patents (Class 424/85.4)
  • Patent number: 11505558
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: April 1, 2021
    Date of Patent: November 22, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Adam Szymaniak, Kevin McGrath, Jianming Yu, Tyler Mann, Long Nguyen, Kaicheng Zhu, In Jong Kim, Yat Sun Or
  • Patent number: 11472778
    Abstract: The invention provides novel classes of HCV therapeutics that are orally available, safe and effective HCV NS3/4A protease inhibitors and are less susceptible to drug resistance than existing therapeutics. The invention also relates to pharmaceutical composition of these compounds and methods of preparation and use thereof.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: October 18, 2022
    Assignee: University of Massachusetts
    Inventors: Celia Schiffer, Akbar Ali, Ashley Matthew
  • Patent number: 11395848
    Abstract: Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: July 26, 2022
    Assignee: ORAMED LTD.
    Inventor: Miriam Kidron
  • Patent number: 11365233
    Abstract: Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the CM1 and the CM2 function as a substrate for a protease; the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: June 21, 2022
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Sayantan Mitra, Nicole G. Lapuyade, Hikmat Haizar Assi, Madan M. Paidhungat, Dylan L. Daniel, Erwan Le Scolan, Walter A. Bogdanoff, Na Cai, Hsin Wang
  • Patent number: 11359089
    Abstract: Disclosed in the present invention is a method for preparing a Y-branched hydrophilic polymer carboxylic acid derivative, in particular a method for preparing a Y-branched polyethylene glycol carboxylic acid derivative having a high purity and high molecular weight. The preparation steps are simple, the product of the reaction is easy to be separated, the cost for separation is low, and the purity and yield of the product are high, facilitating the subsequent preparation of other derivatives and medicament conjugates based on the preparation of the carboxylic acid derivative, which is advantageous for industrial scale-up and commercial applications. The prepared Y-branched hydrophilic polymer carboxylic acid derivative (in particular the Y-branched polyethylene glycol carboxylic acid derivative having a high molecular weight) product has a high purity and high commercial application value, in particular in the use of the preparation of medicaments for preventing and/or treating diseases.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: June 14, 2022
    Assignee: JENKEM TECHNOLOGY CO., LTD. (BEIJING)
    Inventors: Xiaomeng Chen, Meina Lin, Rujun Zhang, Xuan Zhao
  • Patent number: 11352387
    Abstract: Disclosed are chemical compounds, the compounds for use in a method of treatment, particularly in a method of prophylaxis or treatment for cancer, a process for preparation of the compounds and pharmaceutical compositions comprising the compounds. The compounds may, in particular, be useful in the treatment of leukaemia, lymphoma and/or solid tumours in Homo sapiens. The compounds are derivatives of cordycepin (3?-deoxyadenosine) having a 2? and/or 5?-amino-acid ester phosphoramidate moiety.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: June 7, 2022
    Assignee: NuCana plc
    Inventors: Hugh Griffith, Christopher McGuigan, Valentina Ferrari, Michaela Serpi, Carmen Jimenez Antunez
  • Patent number: 11278591
    Abstract: The present disclosure provides a single dose form composition to optimize the relationship between the ‘Folate-Cobalamin’ and ‘Choline-Betaine’ pathways. Single dose form compositions disclosed herein ensure an adequate intake of the rate limiting compounds that have been demonstrated to reduce the efficiency of this vital metabolic axis, and methods of use thereof.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: March 22, 2022
    Assignee: Balchem Corporation
    Inventor: Jonathan Bortz
  • Patent number: 11257579
    Abstract: An artificial intelligence (AI) system and methods for management of an autoimmune or inflammatory condition, disorder or disease in a patient for the diagnosis, prognosis, or risk assessment of symptoms thereof. The AI system includes patient and provider applications and a payer application interface accessible via a communications network. The system contains a data-driven recommendation engine using machine learning and/or deep learning based on active monitoring of patients with an autoimmune or inflammatory-related condition, disorder, or disease. The system can alert clinicians to an impending symptom flare and provide a treatment solution that reduces symptom severity, reduces or eliminates the onset.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: February 22, 2022
    Assignee: Progentec Diagnostics, Inc.
    Inventors: Mohan Purushothaman, Arif Latif Sorathia
  • Patent number: 11236153
    Abstract: The present disclosure relates to constructs useful in expressing biotinylated monomers and tetramers produced from these monomers. Specifically, the disclosure provides a construct useful in expressing biotinylated antigen monomers, said construct comprising a viral protein of an ectodomain of Hepatitis C Virus (HCV) envelope glycoprotein E2 or Human Immunodeficiency Virus (HIV) gp140. Further disclosed are methods for production and use of these tetramers in identifying and isolating antigen specific B cells and cloning antibodies thereto.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: February 1, 2022
    Assignees: Emory University, Rutgers, the State University of New Jersey
    Inventors: Arash Grakoui, Joseph Marcotrigiano
  • Patent number: 11207411
    Abstract: The present invention relates to a stabilized pharmaceutical preparation of R27T, the preparation comprising a human interferon beta variant (R27T), an acetate buffer, arginine, trehalose, Poloxamer 188, and methionine. The stabilized R27T pharmaceutical preparation according to the present invention is obtained by the development of a preparation having a novel composition through the substitution of mannitol with trehalose in the composition of a preparation containing mannitol, which was previously studied by the present inventors.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: December 28, 2021
    Assignee: ABION INC.
    Inventors: Heejung Lee, Nam Ah Kim
  • Patent number: 11192875
    Abstract: The present disclosure provides processes for the preparation of a compound of formula: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: December 7, 2021
    Assignee: Gilead Pharmasset LLC
    Inventors: Kevin M. Allan, Shinji Fujimori, Lars V. Heumann, Grace May, Katie Ann Brown, Christopher M. Levins, Ganapati Reddy Pamulapati, Benjamin James Roberts, Keshab Sarma, Martin Gerald Teresk, Xiang Wang, Scott Alan Wolckenhauer
  • Patent number: 11142523
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: October 12, 2021
    Assignee: Bayer Aktiengesellschaft
    Inventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
  • Patent number: 11033524
    Abstract: The present invention provides pharmaceutical compositions and methods for preventing, delaying onset of, or treating diseases or disorders associated with cortico-hippocampal hyperactivity such as epilepsy, using an active agent capable of reducing dihydroorotate dehydrogenase (DHODH) enzyme activity in the central nervous system, optionally together with a pyrimidine nucleobase or an intermediate in the de novo synthesis thereof.
    Type: Grant
    Filed: November 23, 2017
    Date of Patent: June 15, 2021
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Nir Gonen, Boaz Styr, Eytan Ruppin, Inna Slutsky
  • Patent number: 11022608
    Abstract: Compositions, kits and methods for assessing the presence of pathological fibroblasts within a biological sample are provided. In addition, compositions, kits and methods for detecting fibrosis are provided. Also provided are methods for treating fibrosis and conditions characterized with pathological fibroblasts.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: June 1, 2021
    Assignee: Duke University
    Inventors: Paul Ferrell, Salvatore Pizzo, Robin Bachelder
  • Patent number: 10988503
    Abstract: The present application belongs to the field of chemical synthesis, and specifically relates to a six-membered ring-containing nucleoside compound and a preparation method thereof. The present application discloses a six-membered ring-containing nucleoside compound. The structural formula of the nucleoside compound 7 is: where R1 is selected from one of where R2 is hydroxyl or alkynyl.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: April 27, 2021
    Inventors: Min Hu, Dongchun Hong, Weimin Xue
  • Patent number: 10941177
    Abstract: Provided are compounds of Formula I, as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: March 9, 2021
    Assignee: Gilead Sciences, Inc.
    Inventor: Michael O' Neil Hanrahan Clarke
  • Patent number: 10912777
    Abstract: A pharmaceutical composition comprising (i) a therapeutically effective amount of an inhibitor of the oncogene SLC29A2; and (ii) a pharmaceutically acceptable carrier, for use in suppressing proliferation, occurrence, and metastasis of cancer cells overexpressing the oncogene SLC29A2 in a cancer patient, and/or prolonging cancer patient survival. The inhibitor of the oncogene SLC29A2 may be at least one selected from the group consisting of dipyridamole, dilazep, draflzine, nitorbenzylthioinosine, and the derivatives thereof. The composition for use may further comprise sorafenib for the same use.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: February 9, 2021
    Assignee: ACADEMIA SINICA
    Inventors: Yuh-Shan Jou, Roger Shen
  • Patent number: 10912814
    Abstract: Disclosed are pharmaceutical compositions comprising three antiviral compounds. In particular, the pharmaceutical compositions comprise an effective amount of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: February 9, 2021
    Assignee: Gilead Pharmasset LLC
    Inventors: Ben Chal, Elham Nejati, Rowchanak Pakdaman, Dimitrios Stefanidis
  • Patent number: 10906985
    Abstract: The present invention relates, in part, to chimeric proteins comprising consensus interferon, or a variant thereof, and their use as therapeutic agents.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: February 2, 2021
    Assignees: Orionis Biosciences, Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Lennart Zabeau, Jan Tavernier
  • Patent number: 10858550
    Abstract: A compostable biopolymer adhesive may include a starch, a hydroxylic liquid, a preservative mixture, a crystallization inhibitor, and a carbonate, wherein the compostable biopolymer may be free of synthetic materials yet has a long shelf life, is stable at room temperature, and which can be used to make slime for play.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: December 8, 2020
    Inventor: Ana Maria Davidov
  • Patent number: 10799541
    Abstract: The present invention generally relates to dietary supplement and pharmaceutical formulations comprising layered acid protective oral dosage formulations comprising probiotics and provided as single unified or cohesive dosage form units. Each individual acid protective layer of the cohesive dosage form provides one of a different probiotic payload, a different release profile to target delivery of probiotic to a particular region in the gastrointestinal tract, or both different probiotic payloads and release profiles to target delivery of different probiotics to particular regions in the gastrointestinal tract.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: October 13, 2020
    Assignee: PROBI USA, INC.
    Inventors: Timothy Gamble, Anthony Blanch
  • Patent number: 10781206
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R5 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: September 22, 2020
    Assignee: HOFFMANN LA-ROCHE INC.
    Inventors: Taishan Hu, Hong Shen, Xingchun Han
  • Patent number: 10772943
    Abstract: The present invention relates to a liquid formulation containing botulinum toxin and stabilizing agent, and preparation method therefor. A liquid formulation containing botulinum toxin and stabilizing agent according to the present invention be can be easily stored and distributed. It was proved a significant effect on the stabilization of botulinum toxin under suitable conditions according to the temperature and pH of the human body. Thus, it is expected that the pharmaceutical composition of the present invention will greatly contribute to the safe and convenient medical use of botulinum toxin.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: September 15, 2020
    Assignee: HUGEL INC.
    Inventors: Chee Gun Lee, Ji Hyun Oum
  • Patent number: 10767185
    Abstract: The present invention provides a preparation method for PCV2 capsid protein and a pharmaceutical composition containing said capsid protein. The method of the present invention uses a novel arabinose-induced expression vector and thereby improves the synthesis efficiency of said PCV2 capsid protein. On the other hand, the present pharmaceutical composition combines said capsid protein and other favorable components at a proper ratio so that achieves excellent immune-inducing effects.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: September 8, 2020
    Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng Lin, Zeng-Weng Chen, Jyh-Perng Wang, Tzu-Ting Peng, Huei-Yu Lee, Weng-Zeng Huang, Shih-Rong Wang, Cheng-Yao Yang
  • Patent number: 10689394
    Abstract: A compound represented by the following formula (1) is provided: wherein X represents a sulfur atom or —CH?CH—; A1 to A4 each independently represent a carbon atom or a nitrogen atom, and at least one of A1 to A4 is a nitrogen atom; R1 represents any one of a 1,2,3,4-tetrahydroquinolyl group (or a 3,4-dihydro-1(2H)-quinolyl group), a 3,4-dihydro-4,4-dimethyl-1(2H)-quinolyl group, a 2,3,4,5-tetrahydro-1H-1-benzazepinyl group, or a substituent represented by the following formula (2): wherein R4 represents a 2,3,4-trifluorophenyl group, a 4-iodophenyl group, a 2,3-difluorophenyl group, a 3,5-difluorophenyl group, a 5-fluoro-2-methylphenyl group, a 3-pentafluorosulfanylphenyl group, a 2,6-dimethylphenyl group, a 4-benzyloxyphenyl group, a 3,5-bis(trifluoromethyl)biphenyl group, a 4-tert-butylphenyl group, a 3-methoxyphenyl group, an unsubstituted or substituted pyridyl group, or an unsubstituted or substituted naphthyl group; R5 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a l
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: June 23, 2020
    Assignee: THE UNIVERSITY OF TOKYO
    Inventors: Hidenori Ichijo, Kengo Homma, Naomi Tsuburaya, Tetsuo Nagano, Takayoshi Okabe, Hirotatsu Kojima, Manabu Shimonishi, Takao Fujisawa, Norio Shiibata, Tsunehiko Higuchi, Seiichi Nakamura, Hidehiko Nakagawa, Shin-Ichi Ikeda
  • Patent number: 10682369
    Abstract: Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, produce a synergistic effect on the inhibition of HCV polymerase.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: June 16, 2020
    Assignee: Riboscience LLC
    Inventors: Mark Smith, Klaus G. Klumpp
  • Patent number: 10647747
    Abstract: The present invention relates to a compound of the Formula (I)): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: May 12, 2020
    Assignee: S&T GLOBAL INC.
    Inventors: Zhuang Su, Zhengyu Long, Zhennian Huang, Suizhou Yang
  • Patent number: 10555908
    Abstract: A comestible dosage form article for administration to a target subject, the dosage form comprising: an outer capsule comprising a first cap telescopically engageable with a first body; and an inner capsule, within the outer capsule, comprising a second cap telescopically engageable with a second body, wherein the inner capsule is inverted with respect to the outer capsule such that, in an assembled state, the second cap is proximal to the first body and distal to the first cap.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: February 11, 2020
    Assignee: Capsugel Belgium NV
    Inventor: Stefaan Jaak Vanquickenborne
  • Patent number: 10537646
    Abstract: A composition which includes oxyntomodulin and polyethylene glycol polymer (PEG polymer) linked via a reversible linker such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) is disclosed. Pharmaceutical compositions comprising the reverse pegylated oxyntomodulin and methods of using same are also disclosed.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: January 21, 2020
    Assignee: OPKO Biologics Ltd.
    Inventors: Udi Eyal Fima, Oren Hershkovitz
  • Patent number: 10517881
    Abstract: This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: December 31, 2019
    Assignee: POP TEST ONCOLOGY LLC
    Inventors: Randice Lisa Altschul, Neil David Theise, Andreas J. Kesel, Myron Rapkin, Rebecca O'Brien, Anthony Arment
  • Patent number: 10472354
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: November 12, 2019
    Assignee: Bayer Aktiengesellschaft
    Inventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
  • Patent number: 10398762
    Abstract: Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analog.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: September 3, 2019
    Assignee: Oramed Ltd.
    Inventor: Miriam Kidron
  • Patent number: 10364263
    Abstract: Compounds having the following formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, D, E and R1 are as defined herein, are provided. Methods comprising the use of such compounds for the treatment of neurological disorders, such as pantothenate kinase-associated neurodegeneration, and pharmaceutical compositions containing such compounds, and their use in the treatment of neurological disorders, also are provided.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: July 30, 2019
    Assignee: Retrophin, Inc.
    Inventors: Maria Beconi, Daniel Elbaum, Steven Harper, Savina Malancona
  • Patent number: 10350158
    Abstract: Methods of inhibiting the growth of cells or inducing cell death by contacting the cells with or introducing into the cells a composition including a 5? triphosphate, 2? fluoro-modified pyrimidine non-linear single stranded RNA at least 17 nucleotides long with a least 3 base pairings or a 5? triphosphate, 2? fluoro-modified double stranded RNA at least 17 base pairs long in an amount effective to inhibit cell growth, induce cell death or induce cytokine production by the cells. The methods also include administration of the compositions to a subject. The subject may have a proliferative disorder or infectious disease and administration of the compositions provided herein may treat the disorder or disease.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: July 16, 2019
    Assignee: Duke University
    Inventors: Jaewoo Lee, Johannes Urban, Bruce A. Sullenger
  • Patent number: 10259854
    Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-?) mutant molecule. The engineered Ab-IFN-? mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-? fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-? fusion molecules.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: April 16, 2019
    Assignee: ImmunGene Inc
    Inventors: Iqbal Grewal, Sanjay Khare, Michael Gresser, Rashid Syed
  • Patent number: 10238666
    Abstract: This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: March 26, 2019
    Assignee: Pop Test Oncology LLC
    Inventors: Randice Lisa Altschul, Neil David Theise, Andreas J. Kesel, Myron Rapkin, Rebecca O'Brien, Anthony R. Arment
  • Patent number: 10174290
    Abstract: A method for enhancing infectivity of HCMV virus particles is provided.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: January 8, 2019
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Thomas Shenk, Nicole Gudleski O'Regan, Todd M. Greco, Ileana M. Cristea
  • Patent number: 10174016
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: January 8, 2019
    Assignee: BEYER AKTIENGESELLSCHAFT
    Inventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
  • Patent number: 10150806
    Abstract: The invention features compositions and methods for site-specific modification of proteins by incorporation of an aldehyde tag. Enzymatic modification at a sulfatase motif of the aldehyde tag through action of a formylglycine generating enzyme (FGE) generates a formylglycine (FGly) residue. The aldehyde moiety of FGly residue can be exploited as a chemical handle for site-specific attachment of a moiety of interest to a polypeptide.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: December 11, 2018
    Assignee: The Regents of the University of California
    Inventors: Isaac S. Carrico, Brian L. Carlson, Peng Wu, Carolyn Ruth Bertozzi
  • Patent number: 10078086
    Abstract: Embodiments of the invention are directed to methods of diagnosing bacterial infection in a critically ill patient. The methods include obtaining a sample from the patient and determining the patient's level of IL-27 expression. Embodiments of the invention are also directed to methods that include determining both the patient's levels of IL-27 expression and PCT expression and using the combined result to provide a diagnosis of bacterial infection in a critically ill patient.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: September 18, 2018
    Assignee: Childrens Hospital Medical Center
    Inventor: Hector R. Wong
  • Patent number: 10046029
    Abstract: The present invention relates to a combination of at least two different substances, one of which activates the STAT1-signalling cascade and the other of which activates the TNFR1/CD95-signalling cascade in order to induce permanent growth arrest—i.e. senescence—in pre-malignant or malignant tumors or tumor cells. This induction of permanent growth arrest does not depend on cytotoxicity and does not primarily attempt to kill tumor cells, although this may occur. The induction serves to treat and/or prevent tumors by permanent growth arrest. The combination is used for therapeutic or preventative senescence induction in tumors, in which the STAT1- and TNFR1/CD95-signalling cascade can be activated and in which p16lnk4a is present. The invention transfers tumor cells and, contrary to many other therapies, the tumor stem cells, into permanent growth arrest.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: August 14, 2018
    Inventor: Martin Roecken
  • Patent number: 9956191
    Abstract: Disclosed are 5-nitrobenzoate derivatives of Formula I, and the preparation method therefor, wherein R is referred to hydrogen (H), unsubstituted, mono-substituted, di-substituted or tri-substituted benzoyl moiety. 5-Nitrobenzoare derivatives of Formula I do not affect the platelet aggregation, possesses the inhibitory activity related to the tumor cell-induced platelet aggregation (TCIPA), and further specifically inhibits podoplanin-induced platelet aggregation. Therefore, 5-nitrobenzoates of the invention are applicable in its therapeutic use as the novel therapeutic agent in preventing tumor metastasis.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: May 1, 2018
    Inventors: Ching-Ping Tseng, Pei-Wen Hsieh, Yao-Wen Chang
  • Patent number: 9944686
    Abstract: This invention provides a method for treating tumors in a subject, comprising administering to the subject an effective amount of a recombinant interferon, wherein the interferon has the amino acid sequence of SEQ ID NO:2 and is encoded by the nucleotide sequence SEQ ID NO:1, wherein the tumors are selected from the group consisting of skin cancer, basal cell carcinoma, liver cancer, thyroid cancer, rhinopharyngeal cancer, solid carcinoma, prostate cancer, esophageal cancer, pancreatic cancer, superficial bladder cancer, hemangioma, epidermoid carcinoma, cervical cancer, glioma, leucocythemia, acute leucocythemia, chronic leucocythemia, lymphadenoma, and polycythemia vera.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: April 17, 2018
    Assignee: SUPERLAB FAR EAST LIMITED
    Inventor: Guangwen Wei
  • Patent number: 9868727
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: January 16, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Weiguo Liu, Scott D. Edmondson, Zhuyan Guo, Sung-Sau So, Anthony K. Ogawa, Rongze Kuang, Heping Wu, Amjad Ali, Ying-Duo Gao, Yu Jiang, Chunsing Li, Tingting Yu
  • Patent number: 9861574
    Abstract: Methods of inhibiting the growth of cells or inducing cell death by contacting the cells with or introducing into the cells a composition including a 5? triphosphate, 2? fluoro-modified pyrimidine non-linear single stranded RNA at least 17 nucleotides long with a least 3 base pairings or a 5? triphosphate, 2? fluoro-modified double stranded RNA at least 17 base pairs long in an amount effective to inhibit cell growth, induce cell death or induce cytokine production by the cells. The methods also include administration of the compositions to a subject. The subject may have a proliferative disorder or infectious disease and administration of the compositions provided herein may treat the disorder or disease.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: January 9, 2018
    Assignee: Duke University
    Inventors: Jaewoo Lee, Johannes Urban, Bruce A. Sullenger
  • Patent number: 9827213
    Abstract: Provided are an astragalus membranaceus fermentation product and a method of producing the astragalus membranaceus fermentation product, in which a lactic acid bacteria starter or a yeast starter proliferated and cultured in a medium is inoculated into a mixture, in which astragalus membranaceus, sugar, and water are mixed, to be fermented, and then a pH of a fermentation material obtained by fermenting is measured, and the fermentation material having a pH within a predetermined range is filtered and dried to obtain the astragalus membranaceus fermentation product.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: November 28, 2017
    Assignee: COSISBIO CO., LTD.
    Inventors: Terry Cho Hyun, Sang-hurn Park, Dong-goo Kim, Ji-young Shin
  • Patent number: 9820972
    Abstract: Provided are compounds antiviral compounds represented by formula Ia and Ib: that are highly potent as HCV NS5A inhibitors, where the structural variables are as defined herein. These compounds are useful in, for example, inhibiting Hepatitis C virus and treating Hepatitis C virus infections.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: November 21, 2017
    Assignee: AB PHARMA LTD.
    Inventor: Zheng-Yun James Zhan
  • Patent number: 9783589
    Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof for treatment of autoimmune diseases. More specifically, the present invention provides novel genetically engineered fusion molecules comprising an interferon (IFN) molecule attached to an antibody (Ab) which targets an antigen which is differentially expressed or up-regulated on activated T cells as compared to resting T cells, wherein the fusion molecule when contacted to an activated T cell results in induced apoptosis and programmed cell death or impairment of functions of said activated T cell.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: October 10, 2017
    Assignee: IMMUNGENE INC
    Inventors: Iqbal Grewal, Sanjay Khare, Michael Gresser
  • Patent number: 9763923
    Abstract: Provided is a method of reducing senescence in a cell or subject, or treating or preventing a symptom or disease associated therewith, by administering a BRAF inhibitor to the cell or subject.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: September 19, 2017
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Jungwon Keum, Joontae Park, Chulwon Jung, Sangchul Park, Youngsam Lee
  • Patent number: 9718782
    Abstract: The present invention is directed to benzyl urea compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: August 1, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Andrew J. Cooke, Craig A. Stump, Xu-Fang Zhang, Chun Sing Li, Qinghua Mao